These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 9915661)

  • 1. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study.
    Goldberg AC
    Am J Cardiol; 1998 Dec; 82(12A):35U-38U; discussion 39U-41U. PubMed ID: 9915661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.
    Capuzzi DM; Guyton JR; Morgan JM; Goldberg AC; Kreisberg RA; Brusco OA; Brody J
    Am J Cardiol; 1998 Dec; 82(12A):74U-81U; discussion 85U-86U. PubMed ID: 9915666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.
    Morgan JM; Capuzzi DM; Guyton JR
    Am J Cardiol; 1998 Dec; 82(12A):29U-34U; discussion 39U-41U. PubMed ID: 9915660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.
    Guyton JR; Goldberg AC; Kreisberg RA; Sprecher DL; Superko HR; O'Connor CM
    Am J Cardiol; 1998 Sep; 82(6):737-43. PubMed ID: 9761083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD
    Arch Intern Med; 2000 Apr; 160(8):1177-84. PubMed ID: 10789612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-release niacin for modifying the lipoprotein profile.
    Guyton JR
    Expert Opin Pharmacother; 2004 Jun; 5(6):1385-98. PubMed ID: 15163282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid and transaminase concentrations after formulary conversion of Niaspan to Slo-Niacin.
    Byrd C; Mowrey KA
    Am J Health Syst Pharm; 2010 Dec; 67(23):2038-42. PubMed ID: 21098376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
    Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
    Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
    Grundy SM; Vega GL; McGovern ME; Tulloch BR; Kendall DM; Fitz-Patrick D; Ganda OP; Rosenson RS; Buse JB; Robertson DD; Sheehan JP;
    Arch Intern Med; 2002 Jul; 162(14):1568-76. PubMed ID: 12123399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
    Knopp RH; Alagona P; Davidson M; Goldberg AC; Kafonek SD; Kashyap M; Sprecher D; Superko HR; Jenkins S; Marcovina S
    Metabolism; 1998 Sep; 47(9):1097-104. PubMed ID: 9751239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study.
    Sharma M; Sharma DR; Singh V; Panwar RB; Hira HS; Mohan B; Kumar N; Sharma SK; Gupta R
    Vasc Health Risk Manag; 2006; 2(1):87-93. PubMed ID: 17319473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients.
    McKenney JM; Proctor JD; Harris S; Chinchili VM
    JAMA; 1994 Mar; 271(9):672-7. PubMed ID: 8309029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety evaluation of a large niacin therapeutic interchange program.
    Chaffman MO; Webster WB; Winiecki JT
    Ann Pharmacother; 2013 May; 47(5):657-64. PubMed ID: 23613096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The resurgence of niacin: from nicotinic acid to niaspan/laropiprant.
    Markel A
    Isr Med Assoc J; 2011 Jun; 13(6):368-74. PubMed ID: 21809737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
    Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
    Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.
    Bays H; Giezek H; McKenney JM; O'Neill EA; Tershakovec AM
    Metab Syndr Relat Disord; 2012 Aug; 10(4):260-6. PubMed ID: 22400810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
    Ballantyne CM; Davidson MH; McKenney J; Keller LH; Bajorunas DR; Karas RH
    Am J Cardiol; 2008 May; 101(10):1428-36. PubMed ID: 18471454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes.
    Pan J; Van JT; Chan E; Kesala RL; Lin M; Charles MA
    Metabolism; 2002 Sep; 51(9):1120-7. PubMed ID: 12200755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin.
    Keenan JM; Bae CY; Fontaine PL; Wenz JB; Myers S; Huang ZQ; Ripsin C
    J Am Geriatr Soc; 1992 Jan; 40(1):12-8. PubMed ID: 1727841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin.
    Hunninghake DB; McGovern ME; Koren M; Brazg R; Murdock D; Weiss S; Pearson T
    Clin Cardiol; 2003 Mar; 26(3):112-8. PubMed ID: 12685616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.